Pharmacology of levosimendan: Inotropic, vasodilatory and cardioprotective effects

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 5, 2013, Pages 341-349

  Pathak, A ^a,b   Lebrin, M ^a   Vaccaro, A ^a,b   Senard, J M ^a,b   Despas, F ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

acute heart failure; cell protection pathways; inotropic agent; levosimendan; preconditioning; reperfusion damage; sympathetic nervous system; vasodilatory

Indexed keywords

ADENOSINE TRIPHOSPHATE; BRAIN NATRIURETIC PEPTIDE; CALCIUM; CONTRACTILE PROTEIN; CYCLIC AMP; DIURETIC AGENT; LEVOSIMENDAN; MILRINONE; PHOSPHODIESTERASE III; TROPONIN C; TROPONIN I;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ADRENERGIC SYSTEM; CALCIUM CELL LEVEL; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; DATA BASE; DRUG EXPOSURE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART CONTRACTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PERFORMANCE; HEART PROTECTION; HEART VENTRICLE FUNCTION; HUMAN; INOTROPISM; LONG TERM CARE; LONG TERM SURVIVAL; MEDLINE; MORTALITY; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; REVIEW; SENSITIZATION; SMOOTH MUSCLE FIBER; STUNNED HEART MUSCLE; SUDDEN CARDIAC DEATH; SYMPATHETIC TONE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ACUTE HEART FAILURE; CELL PROTECTION PATHWAYS; INOTROPIC AGENT; LEVOSIMENDAN; PRECONDITIONING; REPERFUSION DAMAGE; SYMPATHETIC NERVOUS SYSTEM; VASODILATORY;

ANIMALS; CARDIOTONIC AGENTS; HUMANS; HYDRAZONES; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASODILATOR AGENTS;

EID: 84883557389     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12067     Document Type: Review

References (93)

1. Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, Mebazaa A,. Levosimendan: from basic science to clinical practice. Heart Fail Rev, 2009; 14: 265-275.
2. Parissis JT, Rafouli-Stergiou P, Stasinos V, Psarogiannakopoulos P, Mebazaa A,. Inotropes in cardiac patients: update 2011. Curr Opin Crit Care, 2011; 16: 432-441.
3. 2 consumption in dogs. Am J Physiol Heart Circ Physiol, 2008; 294: H238-H248.
4. Nieminen MS, Bohm M, Cowie MR, et al,. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J, 2005; 26: 384-416.
5. Metra M, Bettari L, Carubelli V, Cas LD,. Old and new intravenous inotropic agents in the treatment of advanced heart failure. Prog Cardiovasc Dis, 2011; 54: 97-106.
6. Thackray S, Easthaugh J, Freemantle N, Cleland JG,. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail, 2002; 4: 515-529.
7. Packer M,. The search for the ideal positive inotropic agent. N Engl J Med, 1993; 329: 201-202.
8. Haikala H, Pollesello P,. Calcium sensitivity enhancers. IDrugs, 2000; 3: 1199-1205.
9. Kass DA, Solaro RJ,. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation, 2006; 113: 305-315.
10. Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C,. Levosimendan: beyond its simple inotropic effect in heart failure. Pharmacol Ther, 2007; 114: 184-197.
11. Sorsa T, Heikkinen S, Abbott MB, et al,. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem, 2001; 276: 9337-9343.
12. 2+-sensitizers that target the cardiac troponin complex. J Mol Cell Cardiol, 2010; 49: 1031-1041.
13. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB,. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol, 1995; 27: 1859-1866.
14. Givertz MM, Andreou C, Conrad CH, Colucci WS,. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships. Circulation, 2007; 115: 1218-1224.
15. Pagel PS, Hettrick DA, Warltier DC,. Left ventricular mechanical consequences of dihydropyridine calcium channel modulation in conscious and anesthetized chronically instrumented dogs. Anesthesiology, 1994; 81: 190-208.
16. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J,. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol, 1998; 31: 741-749.
17. Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z,. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol, 2006; 148: 696-702.
18. 2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol, 1997; 333: 249-259.
19. Kaheinen P, Pollesello P, Levijoki J, Haikala H,. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol, 2001; 37: 367-374.
20. De Witt BJ, Ibrahim IN, Bayer E, Fields AM, Richards TA, Banister RE, Kaye AD, An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg, 2002; 94: 1427-1433, table of contents.
21. Leather HA, Ver Eycken K, Segers P, Herijgers P, Vandermeersch E, Wouters PF,. Effects of levosimendan on right ventricular function and ventriculovascular coupling in open chest pigs. Crit Care Med, 2003; 31: 2339-2343.
22. Grossini E, Molinari C, Caimmi PP, Uberti F, Vacca G,. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br J Pharmacol, 2009; 156: 250-261.
23. Zager RA, Johnson AC, Lund S, Hanson SY, Abrass CK,. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol, 2006; 290: F1453-F1462.
24. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res, 1995; 77: 107-113.
25. Szilagyi S, Pollesello P, Levijoki J, Kaheinen P, Haikala H, Edes I, Papp Z,. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol, 2004; 486: 67-74.
26. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H,. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation, 1998; 98: 2141-2147.
27. Boknik P, Neumann J, Kaspareit G, Schmitz W, Scholz H, Vahlensieck U, Zimmermann N,. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther, 1997; 280: 277-283.
28. Kudej RK, Zhang XP, Ghaleh B, et al,. Enhanced cAMP-induced nitric oxide-dependent coronary dilation during myocardial stunning in conscious pigs. Am J Physiol Heart Circ Physiol, 2000; 279: H2967-H2974.
29. 2+]i in guinea-pig isolated ventricular myocytes. Eur J Pharmacol, 1997; 339: 97-100.
30. Jonsson EN, Antila S, McFadyen L, Lehtonen L, Karlsson MO,. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol, 2003; 55: 544-551.
31. Nieminen MS, Akkila J, Hasenfuss G, et al,. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol, 2000; 36: 1903-1912.
32. Kersten JR, Montgomery MW, Pagel PS, Warltier DC,. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg, 2000; 90: 5-11.
33. Eisen A, Fisman EZ, Rubenfire M, et al,. Ischemic preconditioning: nearly two decades of research. A comprehensive review. Atherosclerosis, 2004; 172: 201-210.
34. + exchange inhibition against ischemia/reperfusion injury. J Am Coll Cardiol, 2001; 37: 957-963.
35. Gross GJ, Peart JN,. KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol, 2003; 285: H921-H930.
36. Pollesello P, Papp Z,. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol, 2007; 50: 257-263.
37. Grover GJ, Garlid KD,. ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol, 2000; 32: 677-695.
38. Kowaltowski AJ, Seetharaman S, Paucek P, Garlid KD,. Bioenergetic consequences of opening the ATP-sensitive K(+) channel of heart mitochondria. Am J Physiol Heart Circ Physiol, 2001; 280: H649-H657.
39. Facundo HT, Fornazari M, Kowaltowski AJ,. Tissue protection mediated by mitochondrial K+ channels. Biochim Biophys Acta, 2006; 1762: 202-212.
40. Parissis JT, Andreadou I, Markantonis SL, et al,. Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis, 2007; 195: e210-e215.
41. Revermann M, Schloss M, Mieth A, et al,. Levosimendan attenuates pulmonary vascular remodeling. Intensive Care Med, 2011; 37: 1368-1377.
42. Roehl AB, Hein M, Loetscher PD, Rossaint J, Weis J, Rossaint R, Coburn M,. Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury. BMC Neurol, 2010; 10: 97.
43. Coburn NG,. Improving survival for gastric cancer patients-the role of the surgeon. J Surg Oncol, 2010; 101: 103-104.
44. Schwarte LA, Picker O, Bornstein SR, Fournell A, Scheeren TW, Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Crit Care Med, 2005; 33: 135-142, discussion 246-247.
45. Heusch G,. Cardioprotection: chances and challenges of its translation to the clinic. Lancet, 2013; 381: 166-175.
46. Jorgensen K, Bech-Hanssen O, Houltz E, Ricksten SE,. Effects of levosimendan on left ventricular relaxation and early filling at maintained preload and afterload conditions after aortic valve replacement for aortic stenosis. Circulation, 2008; 117: 1075-1081.
47. Parissis JT, Paraskevaidis I, Bistola V, et al,. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol, 2006; 98: 1489-1492.
48. Tachibana H, Cheng HJ, Ukai T, Igawa A, Zhang ZS, Little WC, Cheng CP,. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol, 2005; 288: H914-H922.
49. Parissis JT, Panou F, Farmakis D, et al,. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol, 2005; 96: 423-426.
50. Duygu H, Ozerkan F, Zoghi M, et al,. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. Int J Clin Pract, 2008; 62: 228-233.
51. Lunghetti S, Palmerini E, Urselli R, et al,. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure. Cardiol J, 2011; 18: 532-537.
52. Kasikcioglu HA, Uyarel H, Tartan Z, Kasikcioglu E, Ozturk R, Cam N,. Do calcium sensitizers affect right ventricular functions in patients with chronic heart failure Int J Cardiol, 2007; 118: 246-248.
53. Pathak A, Velez-Roa S, Xhaet O, Najem B, van de Borne P,. Dose-dependent effect of dobutamine on chemoreflex activity in healthy volunteers. Br J Clin Pharmacol, 2006; 62: 272-279.
54. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL,. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation, 1986; 73: 913-919.
55. 2+- sensitizing effect but not to stereoselective phosphodiesterase inhibition. Basic Clin Pharmacol Toxicol, 2006; 98: 74-78.
56. Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT,. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol, 2006; 98: 1641-1645.
57. Vallbo AB, Hagbarth KE, Wallin BG,. Microneurography: how the technique developed and its role in the investigation of the sympathetic nervous system. J Appl Physiol, 2004; 96: 1262-1269.
58. Despas F, Trouillet C, Franchitto N, Labrunee M, Galinier M, Senard JM, Pathak A,. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording. Acute Card Care, 2010; 12: 25-30.
59. Tek M, Cavusoglu Y, Demirustu C, et al,. Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure. Turk Kardiyol Dern Ars, 2010; 38: 334-340.
60. Papp JG, Pollesello P, Varro AF, Vegh AS,. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs. J Cardiovasc Pharmacol Ther, 2006; 11: 129-135.
61. Mebazaa A, Nieminen MS, Filippatos GS, et al,. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail, 2009; 11: 304-311.
62. La Rovere MT, Pinna GD, Maestri R, et al,. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. J Am Coll Cardiol, 2009; 53: 193-199.
63. Moertl D, Berger R, Huelsmann M, Bojic A, Pacher R,. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail, 2005; 7: 1156-1163.
64. Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A,. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol, 2009; 53: 2343-2348.
65. Miettinen KH, Lassus J, Harjola VP, et al,. Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail, 2008; 10: 396-403.
66. Aukrust P, Ueland T, Lien E, et al,. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 1999; 83: 376-382.
67. Pasqui AL, Di Renzo M, Maffei S, Pastorelli M, Pompella G, Auteri A, Puccetti L,. Pro/Anti-inflammatory cytokine imbalance in postischemic left ventricular remodeling. Mediators Inflamm, 2010; 2010: 974694.
68. Parissis JT, Adamopoulos S, Antoniades C, et al,. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol, 2004; 93: 1309-1312.
69. Adamopoulos S, Parissis JT, Iliodromitis EK, et al,. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol, 2006; 98: 102-106.
70. Adamopoulos S, Parissis JT, Kremastinos DT,. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail, 2001; 3: 517-526.
71. Parissis JT, Karavidas A, Bistola V, et al,. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis, 2008; 197: 278-282.
72. Grossini E, Caimmi PP, Molinari C, Teodori G, Vacca G,. Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig. J Cardiovasc Pharmacol, 2005; 46: 333-342.
73. Yilmaz MB, Mebazaa A,. In vivo and in vitro evidence for pleiotropic effects of levosimendan in the intensive care setting. Crit Care, 2011; 15: 182.
74. Sandell EP, Hayha M, Antila S, Heikkinen P, Ottoila P, Lehtonen LA, Pentikainen PJ,. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol, 1995; 26 (Suppl 1): S57-S62.
75. Antila S, Sundberg S, Lehtonen LA,. Clinical pharmacology of levosimendan. Clin Pharmacokinet, 2007; 46: 535-552.
76. Antila S, Pesonen U, Lehtonen L, Tapanainen P, Nikkanen H, Vaahtera K, Scheinin H,. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci, 2004; 23: 213-222.
77. Li-Wan-Po A,. Pharmacogenetics and personalized medicine. J Clin Pharm Ther, 2012; 37: 617-619.
78. Kivikko M, Sundberg S, Karlsson MO, Pohjanjousi P, Colucci WS,. Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients. Scand Cardiovasc J, 2011; 45: 86-90.
79. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ,. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther, 2002; 40: 465-471.
80. Takahashi R, Talukder MA, Endoh M,. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol, 2000; 400: 103-112.
81. Puttonen J, Kantele S, Ruck A, Ramela M, Hakkinen S, Kivikko M, Pentikainen PJ,. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment. J Clin Pharmacol, 2008; 48: 445-454.
82. Parissis JT, Farmakis D, Nieminen M,. Classical inotropes and new cardiac enhancers. Heart Fail Rev, 2007; 12: 149-156.
83. Braun JP, Schneider M, Kastrup M, Liu J,. Treatment of acute heart failure in an infant after cardiac surgery using levosimendan. Eur J Cardiothorac Surg, 2004; 26: 228-230.
84. Turanlahti M, Boldt T, Palkama T, Antila S, Lehtonen L, Pesonen E,. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatr Crit Care Med, 2004; 5: 457-462.
85. Hoffman TM,. Newer inotropes in pediatric heart failure. J Cardiovasc Pharmacol, 2011; 58: 121-125.
86. Jalanko M, Kivikko M, Harjola VP, Nieminen MS, Laine M,. Oral levosimendan improves filling pressure and systolic function during long-term treatment. Scand Cardiovasc J, 2011; 45: 91-97.
87. Poder P, Eha J, Sundberg S, et al,. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol, 2004; 44: 1143-1150.
88. Follath F, Cleland JG, Just H, et al,. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet, 2002; 360: 196-202.
89. Moiseyev VS, Poder P, Andrejevs N, et al,. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J, 2002; 23: 1422-1432.
90. Cleland JG, Freemantle N, Coletta AP, Clark AL,. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail, 2006; 8: 105-110.
91. Mebazaa A, Nieminen MS, Packer M, et al,. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA, 2007; 297: 1883-1891.
92. Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J,. The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cancer, 2013; 13: 85-97.
93. Dickstein K, Cohen-Solal A, Filippatos G, et al,. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J, 2008; 29: 2388-2442.